Izzyring

Ethinylestradiol/Etonogestrel, the active ingredients in Izzyring, constitute a combined hormonal contraceptive formulated as a flexible vaginal ring for intravaginal administration. The device releases a steady dose of hormones to inhibit ovulation and create cervical mucus changes, thereby preventing pregnancy in women of reproductive age.

GNH USA supplies Izzyring as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under appropriate regulatory frameworks, with quality‑assured manufacturing and reliable logistics support. The company ensures traceability and compliance with EU standards for each batch.

Izzyring, a combined hormonal contraceptive vaginal ring, is indicated for contraception and family planning by providing continuous hormone delivery.

- Contraception: Provides reliable, reversible prevention of pregnancy for women of reproductive age. - Family planning: Enables scheduled spacing of pregnancies as part of reproductive health management. - Hormonal birth control: Delivers low‑dose estrogen and progestin to suppress ovulation and alter cervical mucus.

Common side effects are generally mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional stomach upset. - Breast tenderness: discomfort or swelling. - Vaginal irritation: redness or discharge at the insertion site. - Spotting: irregular light bleeding between periods.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe hypertension: sudden increase in blood pressure. - Hepatic adenoma: benign liver tumor formation. - Allergic reaction: rash, swelling, or anaphylaxis. - Vision changes: sudden loss of vision or eye pain.

Before prescribing Izzyring, clinicians should evaluate patient risk factors and provide counseling.

- Assess cardiovascular risk: review history of thromboembolism, hypertension, smoking, and age. - Screen for contraindications: liver disease, breast cancer, known pregnancy, or estrogen‑dependent tumors. - Monitor blood pressure: check regularly during use. - Counsel on smoking cessation: advise women over 35 who smoke to stop. - Educate on correct insertion and removal: follow manufacturer instructions to maintain efficacy. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Izzyring may interact with other medicines that affect hormone metabolism or increase clotting risk.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive effectiveness. - Strong CYP3A4 inducers (rifampin, griseofulvin): can lower hormone levels. - Certain antiretroviral protease inhibitors: may increase hormone exposure and side‑effect risk.

Moderate Interactions (Monitor Closely): - St. John’s wort: may decrease contraceptive efficacy. - Antifungal agents (ketoconazole, itraconazole): may raise hormone concentrations. - Diuretics: may affect fluid balance and blood pressure, requiring monitoring.